Evidence map›Paper›PMID 25349960›Full record

Trial reportMenopause (New York, N.Y.)2015

Baseline age and time to major fracture in younger postmenopausal women.

Margaret Lee Gourlay, Robert A Overman, Jason P Fine, Kristine E Ensrud, Carolyn J Crandall, Margery L Gass, John Robbins, Karen C Johnson, Erin S LeBlanc, Catherine R Womack and 3 more

Abstract readClinical TrialComparative Study
In one paragraph

Trial report in Menopause (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Time to Osteoporosis and Major Fracture in Older Men: The MrOS Study.American journal of preventive medicine · 2016
    Article
  5. Review
  6. Targeted assessment of fracture risk in women at midlife.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Margaret Lee GourlayFrom the 1Department of Family Medicine, University of North Carolina, Chapel Hill, NC; 2Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; 3Department of Biostatistics, University of North Carolina, Chapel Hill, NC; 4Department of Medicine, VA Medical Center, Minneapolis, MN; 5Department of Medicine, University of California Los Angeles, Los Angeles, CA; 6The North American Menopause Society, Mayfield Heights, OH; 7University of California at Davis, Sacramento, CA; 8University of Tennessee Health Science Center, Memphis, TN; 9Center for Health Research, Kaiser Permanente Northwest, Portland, OR;10Division of Health Policy and Management, University of Minnesota, Minneapolis, MN; and 11Fred Hutchinson Cancer Research Center, Seattle, WA.
Robert A Overman
Jason P Fine
Kristine E Ensrud
Carolyn J Crandall
Margery L Gass
John Robbins
Karen C Johnson
Erin S LeBlanc
Catherine R Womack
John T Schousboe
Andrea Z LaCroix
Women’s Health Initiative Investigators

Funding

Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
North Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9M
UNC Clinical and Translational Science AwardUL1TR000083 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUNGE, MARSCHALL S. · 2012 to 2013
$11.6M
Secondary Analyses of Osteoporosis Screening in Older MenR01AG046294 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GOURLAY, MARGARET L · 2014 to 2016
$837k
Selective screening for osteoporosis in younger postmenopausal womenK23RR024685 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GOURLAY, MARGARET L · 2007 to 2011
$662k
NCATS NIH HHS UL1 TR000083NCATS NIH HHS UL1TR000083NCATS NIH HHS UL1 TR001111NCATS NIH HHS UL1 TR002489NCRR NIH HHS K23 RR024685NCRR NIH HHS K23RR024685NHLBI NIH HHS HHSN268201100001INHLBI NIH HHS HHSN268201100002INHLBI NIH HHS HHSN268201100003INHLBI NIH HHS HHSN268201100004INHLBI NIH HHS HHSN268201100046CNIA NIH HHS HHSN271201100004CNIA NIH HHS R01 AG046294PHS HHS HSN268201100001CWHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002CWHI NIH HHS HHSN268201100003CWHI NIH HHS HHSN268201100004C
6 · The paper itself

Abstract

objectiveThis study aims to estimate the incidence of first hip or clinical vertebral fracture or major osteoporotic (hip, clinical vertebral, proximal humerus, or wrist) fracture in postmenopausal women undergoing their first bone mineral density (BMD) test before age 65 years.

methodsWe studied 4,068 postmenopausal women, aged 50 to 64 years without hip or clinical vertebral fracture or antifracture treatment at baseline, who were participating in the Women's Health Initiative BMD cohort study. BMD tests were performed between October 1993 and April 2005, with fracture follow-up through 2012. Outcomes were the time for 1% of women to sustain a hip or clinical vertebral fracture and the time for 3% of women to sustain a major osteoporotic fracture before initiating treatment, adjusting for clinical risk factors and accounting for competing risks. Women without osteoporosis and women with osteoporosis on their first BMD test were analyzed separately.

resultsDuring a maximum of 11.2 years of concurrent BMD and fracture follow-up, the adjusted estimated time for 1% of women to have a hip or clinical vertebral fracture was 12.8 years (95% CI, 8.0-20.4) for women aged 50 to 54 years without baseline osteoporosis, 7.6 years (95% CI, 4.8-12.1) for women aged 60 to 64 years without baseline osteoporosis, and 3.0 years (95% CI, 1.3-7.1) for all women aged 50 to 64 years with baseline osteoporosis. Results for major osteoporotic fracture were similar.

conclusionsBecause of very low rates of major osteoporotic fracture, postmenopausal women aged 50 to 64 years without osteoporosis on their first BMD test are unlikely to benefit from frequent rescreening before age 65 years.

Indexed as

PostmenopauseWomen's HealthAge FactorsCohort StudiesFemaleFollow-Up StudiesFractures, BoneHumansMiddle AgedOsteoporosis, PostmenopausalOsteoporotic FracturesRisk AssessmentRisk FactorsUnited States

Identifiers

PMID25349960
PMCPMC4411185

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.